Serelaxin clinical trials
Also written RLX030.
How each study uses serelaxin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 6 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 1
Novartis Pharmaceuticals (13) · Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies (3) · University of Edinburgh (1)
Often tested with
Tested in the same studies.
Terlipressin acetate (1) · Terlipressin (1)
Studies
Open first, then newest update. How each study uses serelaxin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- PK of Serelaxin in Severe Renal Impairment and ESRDCompletedPhase 1Novartis PharmaceuticalsNCT01875523Written as SerelaxinHow we know
- Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)CompletedPhase 2Novartis PharmaceuticalsNCT01546532Written as RLX030How we know
- Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHFTerminatedPhase 3Novartis PharmaceuticalsNCT02007720Written as SerelaxinHow we know
- Study of the Vascular Effects of SerelaxinCompletedPhase 2Novartis PharmaceuticalsNCT01979614Written as SerelaxinHow we know
- Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart FailureTerminatedPhase 2Novartis PharmaceuticalsNCT02151383Written as SerelaxinHow we know
- Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) PatientsTerminatedPhase 3Novartis PharmaceuticalsNCT02064868Written as SerelaxinHow we know
- Serelaxin To Lower Portal PressureCompletedPhase 2University of EdinburghNCT02669875Written as SerelaxinHow we know
- Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart FailureTerminatedPhase 2Novartis PharmaceuticalsNCT02625922Written as SerelaxinHow we know
- Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFCompletedPhase 3Novartis PharmaceuticalsNCT01870778Written as RLX030How we know
- Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart FailureCompletedPhase 2Novartis PharmaceuticalsNCT01982292Written as RLX030 (serelaxin)How we know
- An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal HypertensionCompletedPhase 2Novartis PharmaceuticalsNCT01640964Written as Serelaxin (RLX030)How we know
- Safety and Efficacy of RLX030 in Pregnant Women With Pre- EclampsiaTerminatedPhase 2Novartis PharmaceuticalsNCT01566630Written as RLX030How we know
- Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02002702Written as SerelaxinHow we know
- Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart FailureCompletedPhase 2Novartis PharmaceuticalsNCT01543854Written as RLX030How we know
- Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of LaborCompletedPhase 2Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesNCT00259103Written as SerelaxinHow we know
- Recombinant Human Relaxin for the Treatment of Decompensated CHFTerminatedPhase 2Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesNCT00406575Written as Recombinant human relaxin (rhRlx)How we know
- Evaluation of the Safety of Relaxin in PreeclampsiaSuspendedPhase 1Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesNCT00333307Written as recombinant human relaxinHow we know
Codes
What other systems call serelaxin · ClinicalTrials.gg INT018284
- UNII (FDA) W0122B976YSERELAXINConfirmed FDA, Wikidata
- Wikidata Q7453086serelaxinConfirmed FDA, Wikidata
- NCI Thesaurus C152342SerelaxinOne source FDA
- DrugBank DB05794One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W0122B976Y | SERELAXIN | Confirmed FDA, Wikidata |
| Wikidata | Q7453086 | serelaxin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152342 | Serelaxin | One source FDA |
| DrugBank | DB05794 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.